MedPath

Biofrontera Bioscience GmbH

🇩🇪Germany
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.biofrontera.com

Clinical Trials

23

Active:16
Completed:7

Trial Phases

3 Phases

Phase 1:8
Phase 2:2
Phase 3:6

Drug Approvals

1

EMA:1

Drug Approvals

Ameluz

Authorization Status
Authorised
Approval Date
Dec 13, 2011
EMA

Clinical Trials

Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials

Phase 1
8 (50.0%)
Phase 3
6 (37.5%)
Phase 2
2 (12.5%)

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Phase 3
Active, not recruiting
Conditions
Actinic Keratoses
First Posted Date
2022-12-22
Last Posted Date
2025-07-03
Lead Sponsor
Biofrontera Bioscience GmbH
Target Recruit Count
172
Registration Number
NCT05662202
Locations
🇺🇸

Medical Dermatology Specialists, Phoenix, Arizona, United States

🇺🇸

Alliance Dermatology & Mohs Center, Phoenix, Arizona, United States

🇺🇸

Dermatology Practice, Greenwood Village, Colorado, United States

and more 11 locations

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Phase 2
Active, not recruiting
Conditions
Acne Vulgaris
First Posted Date
2021-10-18
Last Posted Date
2025-07-03
Lead Sponsor
Biofrontera Bioscience GmbH
Target Recruit Count
126
Registration Number
NCT05080764
Locations
🇺🇸

First OC Dermatology, Fountain Valley, California, United States

🇺🇸

Cosmetic Laser Dermatology, San Diego, California, United States

🇺🇸

Dermatology Associates PA of the Palm Beaches, Delray Beach, Florida, United States

and more 6 locations

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Phase 1
Completed
Conditions
Keratosis, Actinic
Actinic Keratosis
Keratosis
First Posted Date
2021-09-29
Last Posted Date
2024-10-17
Lead Sponsor
Biofrontera Bioscience GmbH
Target Recruit Count
112
Registration Number
NCT05060237
Locations
🇺🇸

Medical Dermatology Specialists, Phoenix, Arizona, United States

🇺🇸

Alliance Dermatology & Mohs Center, Phoenix, Arizona, United States

🇺🇸

Dermatology Practice, Greenwood Village, Colorado, United States

and more 6 locations

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

Phase 1
Completed
Conditions
Actinic Keratoses
First Posted Date
2020-03-24
Last Posted Date
2021-11-11
Lead Sponsor
Biofrontera Bioscience GmbH
Target Recruit Count
48
Registration Number
NCT04319159
Locations
🇺🇸

DermResearch Inc., Austin, Texas, United States

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Phase 3
Active, not recruiting
Conditions
Superficial Basal Cell Carcinoma
First Posted Date
2018-06-29
Last Posted Date
2025-04-29
Lead Sponsor
Biofrontera Bioscience GmbH
Target Recruit Count
187
Registration Number
NCT03573401
Locations
🇺🇸

Medical Dermatology Specialists, Phoenix, Arizona, United States

🇺🇸

Alliance Dermatology & Mohs Center, Phoenix, Arizona, United States

🇺🇸

First OC Dermatology, Fountain Valley, California, United States

and more 14 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.